Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21
Abstract Non-alcoholic fatty liver disease (NAFLD) has been shown to influence breast cancer progression, but the underlying mechanisms remain unclear. In this study, we investigated the impact of NAFLD on breast cancer tumor growth and cell viability through the potential mediator, hepatic fibrobla...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-01-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-023-06386-8 |
| _version_ | 1797349648512319488 |
|---|---|
| author | Yue Sui Qingqing Liu Cong Xu Kumar Ganesan Zhen Ye Yan Li Jianmin Wu Bing Du Fei Gao Cailu Song Jianping Chen |
| author_facet | Yue Sui Qingqing Liu Cong Xu Kumar Ganesan Zhen Ye Yan Li Jianmin Wu Bing Du Fei Gao Cailu Song Jianping Chen |
| author_sort | Yue Sui |
| collection | DOAJ |
| description | Abstract Non-alcoholic fatty liver disease (NAFLD) has been shown to influence breast cancer progression, but the underlying mechanisms remain unclear. In this study, we investigated the impact of NAFLD on breast cancer tumor growth and cell viability through the potential mediator, hepatic fibroblast growth factor 21 (FGF21). Both peritumoral and systemic administration of FGF21 promoted breast cancer tumor growth, while FGF21 knockout attenuated the tumor-promoting effects of the high-fat diet. Mechanistically, exogenous FGF21 treatment enhanced the anti-apoptotic ability of breast cancer cells through STAT3 and Akt/FoXO1 signaling pathways, and mitigated doxorubicin-induced cell death. Furthermore, we observed overexpression of FGF21 in tumor tissues from breast cancer patients, which was associated with poor prognosis. These findings suggest a novel role for FGF21 as an upregulated mediator in the context of NAFLD, promoting breast cancer development and highlighting its potential as a therapeutic target for cancer treatment. |
| first_indexed | 2024-03-08T12:33:20Z |
| format | Article |
| id | doaj.art-65a7fbcce13e4d65b5a37bc186a88e3a |
| institution | Directory Open Access Journal |
| issn | 2041-4889 |
| language | English |
| last_indexed | 2024-03-08T12:33:20Z |
| publishDate | 2024-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death and Disease |
| spelling | doaj.art-65a7fbcce13e4d65b5a37bc186a88e3a2024-01-21T12:37:20ZengNature Publishing GroupCell Death and Disease2041-48892024-01-0115111510.1038/s41419-023-06386-8Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21Yue Sui0Qingqing Liu1Cong Xu2Kumar Ganesan3Zhen Ye4Yan Li5Jianmin Wu6Bing Du7Fei Gao8Cailu Song9Jianping Chen10School of Chinese Medicine, The University of Hong KongSchool of Chinese Medicine, The University of Hong KongSchool of Chinese Medicine, The University of Hong KongSchool of Chinese Medicine, The University of Hong KongChengdu University of Traditional Chinese MedicineXiamen UniversitySchool of Pharmacy, Southwest Medical UniversitySouth China Agricultural UniversityChengdu University of Traditional Chinese MedicineSun Yat-Sen University Cancer CenterSchool of Chinese Medicine, The University of Hong KongAbstract Non-alcoholic fatty liver disease (NAFLD) has been shown to influence breast cancer progression, but the underlying mechanisms remain unclear. In this study, we investigated the impact of NAFLD on breast cancer tumor growth and cell viability through the potential mediator, hepatic fibroblast growth factor 21 (FGF21). Both peritumoral and systemic administration of FGF21 promoted breast cancer tumor growth, while FGF21 knockout attenuated the tumor-promoting effects of the high-fat diet. Mechanistically, exogenous FGF21 treatment enhanced the anti-apoptotic ability of breast cancer cells through STAT3 and Akt/FoXO1 signaling pathways, and mitigated doxorubicin-induced cell death. Furthermore, we observed overexpression of FGF21 in tumor tissues from breast cancer patients, which was associated with poor prognosis. These findings suggest a novel role for FGF21 as an upregulated mediator in the context of NAFLD, promoting breast cancer development and highlighting its potential as a therapeutic target for cancer treatment.https://doi.org/10.1038/s41419-023-06386-8 |
| spellingShingle | Yue Sui Qingqing Liu Cong Xu Kumar Ganesan Zhen Ye Yan Li Jianmin Wu Bing Du Fei Gao Cailu Song Jianping Chen Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 Cell Death and Disease |
| title | Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| title_full | Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| title_fullStr | Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| title_full_unstemmed | Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| title_short | Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| title_sort | non alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21 |
| url | https://doi.org/10.1038/s41419-023-06386-8 |
| work_keys_str_mv | AT yuesui nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT qingqingliu nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT congxu nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT kumarganesan nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT zhenye nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT yanli nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT jianminwu nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT bingdu nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT feigao nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT cailusong nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 AT jianpingchen nonalcoholicfattyliverdiseasepromotesbreastcancerprogressionthroughupregulatedhepaticfibroblastgrowthfactor21 |